Triomics' software offerings, Harmony and Prism, integrate with health system EHRs to help with specific care workflows. Harmony curates data for registry, reporting, or research needs, while Prism handles patient-trial matching by pre-screening oncology patients to find relevant clinical trials. The company plans to use the funding to increase its team and scale up the reach of its product, with a goal of partnering with over a dozen institutions by the end of the year.
Key takeaways:
- San Francisco-based startup Triomics has raised $15 million in funding to accelerate cancer care with generative AI. The company has developed a family of large language models (LLMs), called OncoLLM, that streamline complex oncology-related workflows.
- OncoLLM models are customized for each partner institution and deployed across Triomics’ software offerings that integrate with health system EHRs to help with specific care workflows. The company currently has two products: Harmony and Prism.
- Triomics' technology has been tested by the Medical College of Wisconsin Cancer Center, where it outperformed larger open-source and proprietary LLMs at patient-trial matching and rivaled qualified medical experts and GPT-4.
- With the new funding, Triomics plans to increase its team and scale up the reach of the product. The company is targeting to partner with over a dozen institutions by the end of the year.